A Study of ARRY-334543 in Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Advanced Cancer

In brief

This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-334543. This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in order to achieve the highest dose possible that will not cause unacceptable side effects. Approximately 70 patients from the US and Canada will be enrolled in Part 1 (Completed). In the second part of the study, patients will receive the best dose(s) and schedule(s) of study drug determined from the first part of the study and will be followed to see what side effects the study drug causes and what effectiveness it has, if any, in treating the cancer. Approximately 40 patients from the US and Canada will be enrolled in Part 2 (Completed).

Key facts

Study ID

NCT00278902

Run by

Array Biopharma, now a wholly owned subsidiary of Pfizer

People needed

96

Starts

2006-01-01

Expected to finish

2009-06-01

Last updated by the study team

2020-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Sarah Cannon Research Center — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• British Columbia Cancer Agency- Centre for the Southern Interior — Kelowna, British Columbia, Canada
• British Columbia Cancer Agency — Vancouver, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.